Quote | Black Diamond Therapeutics Inc. (NASDAQ:BDTX)
Last: | $5.30 |
---|---|
Change Percent: | -0.35% |
Open: | $5.72 |
Close: | $5.30 |
High: | $5.72 |
Low: | $5.13 |
Volume: | 1,861,848 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Black Diamond Therapeutics Inc. (NASDAQ:BDTX)
2024-04-08 08:00:07 ET Robert Driscoll from Wedbush issued a price target of $16.00 for BDTX on 2024-04-08 07:07:00. The adjusted price target was set to $16.00. At the time of the announcement, BDTX was trading at $5.06. The overall price target consensus is at $12.00 w...
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib ...
Message Board Posts | Black Diamond Therapeutics Inc. (NASDAQ:BDTX)
Subject | By | Source | When |
---|---|---|---|
$BDTX: See UP-dated 'Chart', below!!! | Invest-in-America | investorshub | 06/27/2023 5:21:25 PM |
$BDTX: See the 'CHART', right now, below!!! | Invest-in-America | investorshub | 06/27/2023 5:00:37 PM |
$BDTX: Are you feelin' LUCKY?? Bet your damn | Invest-in-America | investorshub | 06/27/2023 4:54:31 PM |
Wild | Awl416 | investorshub | 06/27/2023 4:31:02 PM |
$BDTX: Hey, Mr. dcaf7, I'm tryin' to get | Invest-in-America | investorshub | 06/27/2023 4:22:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
2024-04-08 08:00:07 ET Robert Driscoll from Wedbush issued a price target of $16.00 for BDTX on 2024-04-08 07:07:00. The adjusted price target was set to $16.00. At the time of the announcement, BDTX was trading at $5.06. The overall price target consensus is at $12.00 w...
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib ...
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Clinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical EGFRm NSCLC Oral presentation at AACR annual meeting in ...